EGFR and lung adenocarcinoma: The identification of druggable driver mutations and rearrangements (e.g., EGFR mutations, ALK, ROS1 and RET-fusions) routinely detected in approximately 15% of NSCLCs has dramatically changed the therapeutic approach for lung adenocarcinoma in the last ten years.